Skip to content

Study · Randomized controlled trial · n = 131 · 2005

6 results

A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy.

Xavier P, Gamboa C, Calejo L, Silva J, Stevenson D, Nunes A, Martinez-de-Oliveira J

European journal of obstetrics, gynecology, and reproductive biology1 Jun 2005Cited by 31 (Europe PMC)

PMID15925049 (opens in a new tab)DOI10.1016/j.ejogrb.2004.11.005 (opens in a new tab)PepBankPUB-15925049
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In COS patients, stimulation duration was shorter with cetrorelix than the agonist protocol: 9.5+/-1.7 versus 10.6+/-2.1 days, P=0.02.

    In plain wordsIn COS patients, stimulation lasted fewer days with cetrorelix than the agonist protocol.

    Peptide
    Cetrorelix
    Outcome
    DecreaseStimulation duration
    Study

    n = 131

    Comparator
    Busereline agonist protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Stimulation duration
    9.5 days
    cetrorelix
    SD
    1.7 days
    cetrorelix
    Stimulation duration
    10.6 days
    agonist
    SD
    2.1 days
    agonist
    P
    0.02
    between protocols

    Source sentences

    Summary
    The mean (+/-S.D.) duration of stimulation was 9.5+/-1.7 days in the antagonist group and 10.6+/-2.1 days in the agonist group (P=0.02).
    2 context sentences
    Summary · context
    Phase III, randomized, single center study of 131 patients undergoing COS and IVF with or without ICSI, in a University affiliated Hospital.
    Summary · context
    Sixty-six patients were allocated to the protocol with antagonist and 65 to the agonist protocol arm.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In COS patients, suppression duration was shorter with cetrorelix than the agonist protocol: 4.6+/-1.3 versus 27.3+/-5.2 days, P<0.0001.

    In plain wordsIn COS patients, suppression lasted fewer days with cetrorelix than the agonist protocol.

    Peptide
    Cetrorelix
    Outcome
    DecreaseSuppression duration
    Study

    n = 131

    Comparator
    Busereline agonist protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Suppression duration
    4.6 days
    cetrorelix
    SD
    1.3 days
    cetrorelix
    Suppression duration
    27.3 days
    agonist
    SD
    5.2 days
    agonist
    P
    < 0.0001
    between protocols

    Source sentences

    Summary
    The mean (+/-S.D.) duration of suppression was 4.6+/-1.3 days in the antagonist group and 27.3+/-5.2 days in the agonist group (P<0.0001).
    2 context sentences
    Summary · context
    Phase III, randomized, single center study of 131 patients undergoing COS and IVF with or without ICSI, in a University affiliated Hospital.
    Summary · context
    Sixty-six patients were allocated to the protocol with antagonist and 65 to the agonist protocol arm.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In COS patients, rFSH use, estradiol, follicle count, endometrial thickness, oocyte count and fertilization did not differ significantly between cetrorelix and agonist protocols.

    In plain wordsIn COS patients, the listed stimulation outcomes did not differ significantly between cetrorelix and agonist protocols.

    Peptide
    Cetrorelix
    Outcome
    No significant changeOther ovarian stimulation outcomes
    Study

    n = 131

    Comparator
    Busereline agonist protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant differences were noted in other outcome measures: amount of rFSH required, estradiol level on hCG day, number of follicles>or=15 mm and endometrial thickness on oocyte retrieval day, number of oocytes retrieved, fertilization rate and number of OHS cases.
    2 context sentences
    Summary · context
    Phase III, randomized, single center study of 131 patients undergoing COS and IVF with or without ICSI, in a University affiliated Hospital.
    Summary · context
    Sixty-six patients were allocated to the protocol with antagonist and 65 to the agonist protocol arm.
  4. 04HumanRandomized controlled trialSafety outcome

    In COS patients, OHS case numbers did not differ significantly between cetrorelix and agonist protocols.

    In plain wordsIn COS patients, ovarian hyperstimulation cases did not differ significantly between cetrorelix and agonist protocols.

    Peptide
    Cetrorelix
    Outcome
    No significant changeOHS cases
    Study

    n = 131

    Comparator
    Busereline agonist protocol
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant differences were noted in other outcome measures: amount of rFSH required, estradiol level on hCG day, number of follicles>or=15 mm and endometrial thickness on oocyte retrieval day, number of oocytes retrieved, fertilization rate and number of OHS cases.
    2 context sentences
    Summary · context
    Phase III, randomized, single center study of 131 patients undergoing COS and IVF with or without ICSI, in a University affiliated Hospital.
    Summary · context
    Sixty-six patients were allocated to the protocol with antagonist and 65 to the agonist protocol arm.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In COS patients, pregnancy per attempt was 15.1% with cetrorelix versus 16.9% with the agonist protocol, P=0.79.

    In plain wordsIn COS patients, pregnancy per attempt did not differ significantly between cetrorelix and the agonist protocol.

    Peptide
    Cetrorelix
    Outcome
    No significant changeClinical pregnancy per attempt
    Study

    n = 131

    Comparator
    Busereline agonist protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Clinical pregnancy per attempt
    15.1%
    cetrorelix
    Clinical pregnancy per attempt
    16.9%
    agonist
    P
    0.79
    per-attempt comparison

    Source sentences

    Summary
    Clinical pregnancy rates per-attempt and per-transfer were 15.1% and 17.0% in the antagonist group and 16.9% and 20.0% in the agonist group (P=0.79 and 0.71, respectively).
    2 context sentences
    Summary · context
    Phase III, randomized, single center study of 131 patients undergoing COS and IVF with or without ICSI, in a University affiliated Hospital.
    Summary · context
    Sixty-six patients were allocated to the protocol with antagonist and 65 to the agonist protocol arm.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In COS patients, pregnancy per transfer was 17.0% with cetrorelix versus 20.0% with the agonist protocol, P=0.71.

    In plain wordsIn COS patients, pregnancy per transfer did not differ significantly between cetrorelix and the agonist protocol.

    Peptide
    Cetrorelix
    Outcome
    No significant changeClinical pregnancy per transfer
    Study

    n: not reported in source

    Comparator
    Busereline agonist protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Clinical pregnancy per transfer
    17%
    cetrorelix
    Clinical pregnancy per transfer
    20%
    agonist
    P
    0.71
    per-transfer comparison

    Source sentences

    Summary
    Clinical pregnancy rates per-attempt and per-transfer were 15.1% and 17.0% in the antagonist group and 16.9% and 20.0% in the agonist group (P=0.79 and 0.71, respectively).
    2 context sentences
    Summary · context
    Phase III, randomized, single center study of 131 patients undergoing COS and IVF with or without ICSI, in a University affiliated Hospital.
    Summary · context
    Sixty-six patients were allocated to the protocol with antagonist and 65 to the agonist protocol arm.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.